About half of the surveyed members of the Society of Breast Imaging have adopted FDA-approved artificial intelligence tools for breast cancer detection, according to The Decoder. The survey included 215 members, highlighting a growing integration of AI technology in clinical practice.
However, the results reveal a gap between expectations and outcomes. While 59% of respondents anticipated that AI would reduce recall rates, only 35% reported an actual decrease. This suggests that current AI tools may not yet fully meet clinical hopes for improving diagnostic efficiency.
For Japanese markets, where breast cancer screening and AI-driven healthcare solutions are evolving, these findings underscore the need for cautious optimism and continued evaluation of AI effectiveness in real-world settings.